Crispr Therapeutics Ag (NQ: CRSP )
70.21 -0.93 (-1.31%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Press Releases about Crispr Therapeutics Ag
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 16, 2023
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Topics Artificial Intelligence
Exposures Artificial Intelligence
MarketBeat: Week in Review 8/1 - 8/5
August 06, 2022
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.
Why Orphan Drug Designation Offers Several Benefits
May 18, 2022
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we...
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
June 11, 2021